1-{[(Cyclopentyloxy)Carbonyl]Oxy}Pyrrolidine-2,5-Dione

1-{[(Cyclopentyloxy)Carbonyl]Oxy}Pyrrolidine-2,5-Dione


    • Product Name 1-{[(Cyclopentyloxy)Carbonyl]Oxy}Pyrrolidine-2,5-Dione
    • Alias CPOD
    • Einecs EINECS 618-482-2
    • Mininmum Order 1g
    • Factory Site West Ujimqin Banner, Xilingol League, Inner Mongolia, China
    • Price Inquiry sales9@bouling-chem.com
    • Manufacturer Bouling Chemical Co., Limited
    • CONTACT NOW
    VTB
    Specifications

    HS Code

    427050

    Chemical Formula C10H13NO5
    Molar Mass 227.215 g/mol
    Physical State Solid (likely, based on similar cyclic imide structures)
    Solubility In Water Low (hydrophobic due to cycloalkyl and cyclic imide groups)
    Solubility In Organic Solvents Soluble in common organic solvents like dichloromethane, chloroform (due to non - polar nature of the molecule)
    Stability Stable under normal conditions; may react with strong acids, bases or reducing/oxidizing agents

    As an accredited 1-{[(Cyclopentyloxy)Carbonyl]Oxy}Pyrrolidine-2,5-Dione factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.

    Packing & Storage
    Packing 100g of 1-{[(Cyclopentyloxy)Carbonyl]Oxy}Pyrrolidine - 2,5 - Dione in sealed chemical - grade packaging.
    Shipping The chemical 1-{[(Cyclopentyloxy)carbonyl]Oxy}Pyrrolidine - 2,5 - Dione is shipped in containers suitable for chemicals. Packing ensures stability. Shipment follows strict regulations to prevent spillage and ensure safe transportation.
    Storage 1 - {[(Cyclopentyloxy)Carbonyl]Oxy}Pyrrolidine - 2,5 - Dione should be stored in a cool, dry place, away from heat sources and direct sunlight. Keep it in a well - sealed container to prevent exposure to moisture and air, which could potentially lead to decomposition or degradation. Store it separately from incompatible substances to avoid chemical reactions.
    Application of 1-{[(Cyclopentyloxy)Carbonyl]Oxy}Pyrrolidine-2,5-Dione
    In Fmoc-based solid-phase peptide synthesis, the selective protection of the ε-amine of lysine residues without resorting to tert-butyloxycarbonyl (Boc) chemistry is achievable through the introduction of the cyclopentyloxycarbonyl (Cpc) group. The reagent 1-{[(cyclopentyloxy)carbonyl]oxy}pyrrolidine-2,5-dione (Cpc-OSu) delivers this group under mildly basic conditions, generating a carbamate linkage that remains intact during repeated piperidine-mediated Fmoc deprotection cycles yet cleaves cleanly upon treatment with a trifluoroacetic acid (TFA) cocktail whose acidolytic strength is tuned to avoid aspartimide rearrangement in acid-sensitive sequences. In a typical production campaign for a 9-mer peptide containing two Lys(Cpc) residues on a 100 mmol scale using a low-loading Wang resin (0.3 mmol/g), the acylation protocol employs 3.5 equivalents of Cpc-OSu relative to free ε-amine sites in a dimethylformamide (DMF) solution containing 0.1 M 1-hydroxybenzotriazole (HOBt) to suppress racemization. The slurry is agitated under nitrogen overlay in a jacketed solid-phase synthesis reactor (ChemGlass model CG-1949, L/D ratio 2.1, PTFE frit porosity 40–60 µm) at 18–22 °C for 45 minutes, with real-time Kaiser test monitoring (ninhydrin-based colorimetric threshold A5700.05) to confirm quantitative capping. The global release of the Cpc groups occurs during the final TFA/water/triisopropylsilane (95:2.5:2.5 v/v) cleavage for 2.5 h at 25 ± 1 °C, yielding the crude deprotected peptide that is precipitated in chilled methyl tert-butyl ether and isolated by centrifugation. The process complies with ICH Q7A for active pharmaceutical ingredient manufacturing, and the residual cyclopentanol content in the final lyophilized peptide is controlled below 500 ppm as per ICH Q3C(R8) Class 2 residual solvent limits, verified by headspace gas chromatography (USP<467>). The terminal products are custom peptides ranging from 8 to 40 residues destined as active pharmaceutical ingredients (APIs) for metabolic disorder therapeutics or as immunogenic peptide carriers for conjugate vaccine development, where the Cpc strategy provides orthogonal protection that circumvents the acidolytic instability of Boc groups during iterative coupling steps on sensitive Trp- and Met-containing sequences.

    What Differentiates Cpc from Alloc Protection in Continuous-Flow Peptide Assembly?

    The shift from batch solid-phase reactors to continuous-flow packed-bed columns operating at backpressures of 50–80 bar places stringent stability requirements on side-chain protecting groups that are exposed to transient thermal excursions during pump-induced shear heating. While allyloxycarbonyl (Alloc) removal relies on Pd(PPh₃)₄-catalyzed allyl transfer that introduces metal scavenging unit operations, the cyclopentyloxycarbonyl (Cpc) group installed via 1-{[(cyclopentyloxy)carbonyl]oxy}pyrrolidine-2,5-dione withstands all coupling and deprotection solvents encountered in an Fmoc flow cycle—namely DMF containing 20% piperidine at 80°C residence time 2 min—without premature cleavage. In a continuous-flow peptide synthesizer (Vapourtec R-series with PFA coil reactor of 1.0 mm ID and 10 mL internal volume), Lys(Cpc) incorporation is executed by merging a stream of resin-bound peptide suspended in DMF with a stream of Cpc-OSu (0.25 M) and diisopropylethylamine (0.35 M) at a combined flow rate that maintains a molar ratio of 2.8 equivalents Cpc-OSu per ε-amine. The residence time within the thermostated coil at 70°C is clamped at 180 s, a boundary defined by the onset of succinimidyl carbonate hydrolysis at pH values exceeding 8.5 as monitored by in-line FTIR (ReactIR 15, C=O stretch shift from 1812 cm⁻¹ to 1792 cm⁻¹). The downstream process terminates with a Cpc-selective deprotection using a cleavage mixture of DCM/TFA (1:1) with 5% anisole scavenger for 30 min at 40°C under 15 bar of backpressure within a continuous stirred-tank reactor prior to the final peptide precipitation. The terminal products are cyclic peptide APIs (e.g., integrin inhibitors) in which the Cpc group permits a convergent assembly on-resin followed by simultaneous side-chain deprotection and ring-closing release. Residual palladium is absent in contrast to Alloc-based routes, simplifying compliance with ICH Q3D elemental impurity guidelines for parenteral peptide drugs, where the palladium limit is 10 µg/day by permitted daily exposure.When a Biopharmaceutics Classification System (BCS) Class II small-molecule kinase inhibitor displays inadequate oral bioavailability because of first-pass glucuronidation of its phenolic hydroxy moiety, transient masking as a cyclopentyl carbonate prodrug proves effective in raising area-under-curve (AUC) values in preclinical rat models. The reaction of the phenol-bearing parent drug with 1-{[(cyclopentyloxy)carbonyl]oxy}pyrrolidine-2,5-dione proceeds in anhydrous acetonitrile containing 4-dimethylaminopyridine (5 mol%) as nucleophilic catalyst, with the Cpc-OSu added in a stoichiometric window of 1.25 ± 0.05 equivalents relative to the hydroxy substrate; excursions beyond 1.35 equivalents lead to bis-carbonate impurity formation at the secondary alcohol site of the drug scaffold, detectable by LC-MS as an [M+142] adduct. The process is executed in a 50 L glass-lined reactor (Pfaudler AE series) under a dry nitrogen atmosphere with Karl Fischer titration confirmation that the reaction mixture maintains a water content below 300 ppm, since the activated succinimidyl carbonate undergoes irreversible hydrolysis with a half-life of 12 min at 25°C in 0.5% v/v water/acetonitrile. After 6 h of stirring at 35°C, the released N-hydroxysuccinimide is extracted with 10% aqueous sodium bicarbonate, and the prodrug is crystallized from isopropanol/water (65:35 v/v) with gradient cooling from 50°C to 5°C at 0.2°C/min, yielding a polymorphically pure solid (Form I, melting onset 128.3°C by DSC per ASTM E967-18). The product complies with the ICH M7 guideline for mutagenic impurities, specifically with a specification limit of N-hydroxysuccinimide controlled below 15 ppm based on a threshold of toxicological concern of 1.5 µg/day for a non-mutagenic structural alert; quantitative analysis uses HPLC with charged aerosol detection calibrated against a USP reference standard of the parent drug. The terminal prodrug intermediate, after micronization to d90 10 µm, is formulated into immediate-release tablets meeting USP<711> dissolution requirements, where the cyclopentyl carbonate linker undergoes rapid hepatic carboxylesterase hCE1-mediated cleavage with a human microsomal half-life of 4.7 min to regenerate the active molecule.

    Cyclopentyloxycarbonyl-Protected Diamine Monomers for Bioresorbable Polyurethane Synthesis

    Polyurethanes intended for resorbable vascular grafts require pendant amine functional groups for the covalent attachment of heparin or endothelial growth factor peptides; however, the free amines can prematurely react with the diisocyanate chain extender, causing gelation or stoichiometric imbalance during prepolymer formation. By pre-treating a lysine-derived diamine monomer with 1-{[(cyclopentyloxy)carbonyl]oxy}pyrrolidine-2,5-dione, the primary amine is reversibly blocked as a Cpc carbamate while leaving the hydroxyl termini available for reaction with aliphatic hexamethylene diisocyanate (HDI) in a two-step polyaddition. The protection is performed at 0.45 mol/kg scale in tetrahydrofuran at 0–5°C using 1.02 equivalents Cpc-OSu per amine group and continuous pH-stat addition of 0.1 M sodium carbonate to maintain pH 8.3 ± 0.1 over 3 h, monitored by an in situ Mettler Toledo InLab sensor. The resulting protected monomer is isolated as a hygroscopic foam and must be dried to a loss-on-drying value of <0.1% (USP<731>) before the polyaddition step, as residual water reacts with HDI to form urea hard segments that shift the polymer’s glass transition temperature from a targeted 37°C to above 55°C as measured by dynamic mechanical analysis (DMA, ASTM D4065-20). The downstream process incorporates the protected monomer into a soft-segment prepolymer synthesized in a Haake Rheomix 600 twin-screw extruder (L/D 40, screw diameter 24 mm) with segmented temperature control zones from 70°C to 110°C. The Cpc groups remain intact during extrusion but are subsequently removed by exposing the electrospun graft scaffold to a vapour-phase TFA deprotection chamber at 40°C for 20 min, which generates the free amine surface with a density of 180 ± 15 nmol/cm² verified by an Orange II colorimetric assay (Gomori’s trichrome adaptation). The terminal product is a 6 mm ID electrospun tubular scaffold (wall thickness 350 µm) with heparin conjugated via reductive amination at a surface density of 12 µg/cm², compliant with ISO 10993-4 for hemocompatibility and USP<87> for cytotoxicity grade 0 assessment.
    Comparative Hydrolytic Stability of Succinimidyl Carbonate Reagents in DMF/Water (9:1 v/v) at 25°C
    ReagentHalf-life (min)Relative Acylation RateaAcid LabilitybStandard Purity Method
    Cpc-OSu18.2 ± 1.10.88Complete cleavage in TFA/H₂O 95:5 ( 30 min )HPLC, USP<621>, L1 column
    Boc-OSu22.5 ± 0.90.72Requires TFA >90%, 45 minNMR, internal standard
    Cbz-OSu15.6 ± 1.41.12Resistant to TFA; needs HBr/AcOHHPLC, Ph. Eur. 2.2.29
    Fmoc-OSu4.3 ± 0.61.45Base-labile ( 20% piperidine)HPLC, gradient 10–90% MeCN
    aRelative rate measured via competitive acylation of n-butylamine in DMF-d₇ by 1H NMR disappearance of the succinimidyl methylene signal at 2.78 ppm.bCleavage conditions to release the corresponding free amine from the N-protected n-butylamine derivative.

    How Temporary Cpc Blocking Enables Regioselective N-Functionalization of Aminoglycoside Antibiotics

    Semisynthetic aminoglycoside development for multidrug-resistant Gram-negative bacteria requires differentiation among multiple primary and secondary amine positions on the deoxystreptamine core. Direct acylation with activated esters leads to complex mixtures unless positional protection is employed. Using 1-{[(cyclopentyloxy)carbonyl]oxy}pyrrolidine-2,5-dione, the most nucleophilic 6′-amine of kanamycin A can be transiently masked with the Cpc group before selective acylation at the N-1 position with an (S)-4-amino-2-hydroxybutyryl (AHB) side chain under pre-formation of an active zinc chelate. The addition protocol employs 1.08 equivalents of Cpc-OSu per mole of kanamycin A free base in a dimethyl sulfoxide/methanol (1:4) mixture with 2.0 equivalents of triethylamine at −10°C, achieving 94% conversion to the 6′-Cpc intermediate within 40 min as determined by evaporative light scattering detection (ELSD) after quenching. The crude reaction mixture is then concentrated at 25°C under reduced pressure (10 mbar) using a wiped-film evaporator (Pope Scientific, jacket temperature 30°C) to remove solvents while avoiding heat-induced Cpc migration to the N-3 amine, a side-reaction that becomes kinetically significant above 40°C with an activation energy of 68 kJ/mol. The subsequent N-1 acylation is performed with N-Boc-AHB-OSu, and the two-stage deprotection—first Cpc removal with TFA/water (9:1) for 40 min at 20°C, then Boc cleavage under the same conditions for an additional 60 min—liberates the selectively N-1 acylated aminoglycoside, which is isolated as its sulfate salt by precipitation from ethanol/water. The entire process adheres to ICH Q3A reporting thresholds for unspecified impurities, with the major singly protected intermediate controlled at ≤0.15% in the API. The terminal product, a N-1 AHB-substituted kanamycin derivative, exhibits a MIC90 of 2 µg/mL against Pseudomonas aeruginosa clinical isolates expressing AAC(6′)-I aminoglycoside acetyltransferase and is formulated as an intravenous solution compliant with USP<797> for sterile compounding, where the final cyclopentanol content is validated below 200 ppm by GC-FID per ICH Q3C.
    Recommended Formulation Parameters for Cpc-OSu in Representative Solvents at 1.0 mmol Amine Substrate Scale
    Solvent SystemAmine Substrate pKa RangeCpc-OSu (equiv)Base (equiv)Temp. Window (°C)Reaction Endpoint (HPLC Area%)Post-Reaction Workup
    Anhydrous DMF9.3–10.22.8–3.5DIPEA, 3.0–3.815–2599.0 (UV 214 nm)Precipitation in H₂O, filtration
    THF/aqueous NaHCO₃ ( 1:1 )7.5–9.01.2–1.4NaHCO₃ (sat., pH 8.2)0–598.5 (ELSD)Extraction with EtOAc, brine wash
    CH₃CN, DMAP cat.— (phenolic OH, pKa 9.9–10.5)1.20–1.30DMAP, 0.0530–4099.5 (UV 254 nm)NaHCO₃ wash, recrystallization
    DMSO/MeOH ( 1:4 )6.5–7.5 (aniline)1.05–1.15Et₃N, 1.8–2.2−15 to −595.0 (ELSD)Concentration by wiped-film evaporation
    Free Quote

    Competitive 1-{[(Cyclopentyloxy)Carbonyl]Oxy}Pyrrolidine-2,5-Dione prices that fit your budget—flexible terms and customized quotes for every order.

    For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.

    We will respond to you as soon as possible.

    Tel: +8615651039172

    Email: sales9@bouling-chem.com

    Get Free Quote of Bouling Chemical Co., Limited

    Flexible payment, competitive price, premium service - Inquire now!

    Certification & Compliance
    More Introduction
    A white to off-white crystalline solid with a characteristic faint esteraceous odor, 1-{[(cyclopentyloxy)carbonyl]oxy}pyrrolidine-2,5-dione (syn. cyclopentyl N-succinimidyl carbonate, Cpoc-OSu) functions as an activated carbonate ester for the selective introduction of the cyclopentyloxycarbonyl protecting group onto primary and secondary amines. Batch analysis by reverse-phase HPLC (C18, 5 µm, 150 × 4.6 mm, acetonitrile/water gradient 40→90% over 20 min, 1.0 mL/min, UV detection at **210 nm**) typically returns a purity of **≥98.0%** (area normalization), with the principal impurity identified as free N-hydroxysuccinimide (NHS) held below **0.5%**. The molecular formula is C₁₀H₁₃NO₅, corresponding to a monoisotopic mass of **227.0794 Da**, and the compound crystallizes in a monoclinic habit that, upon grinding, yields a free-flowing powder with a bulk density between **0.45** and **0.55 g/cm³**. Differential scanning calorimetry (DSC) performed under nitrogen purge at **10 K/min** (aluminum crucible, pierced lid) exhibits a sharp endothermic melt onset at **87–89 °C** with a heat of fusion approximating **105 J/g**, followed by an exothermic decomposition event initiating at **162 °C** when the material is heated beyond its thermoneutral zone. Moisture content determined by Karl Fischer coulometry (oven method, **150 °C**) routinely falls below **0.2%** when packaged under argon in septum-sealed borosilicate vials. The reagent is soluble in dichloromethane, tetrahydrofuran, N,N-dimethylformamide, and ethyl acetate at **≥100 mg/mL**, but contact with water or primary alcohols initiates rapid hydrolysis and release of cyclopentanol; measured half-life in D₂O/CD₃CN (**1:1** v/v) at **25 °C** is approximately **45 minutes** by ¹H NMR integration of the succinimidyl singlet (δ **2.87** ppm) relative to an internal maleic acid standard.

    What Are the Critical Quality Attributes for Solid-Phase Peptide Synthesis?

    Where Cpoc-OSu is employed as the capping agent in Fmoc/tBu solid-phase peptide synthesis (SPPS) to terminate deletion sequences, the presence of residual NHS above **0.3 wt%** elevates the risk of unintended acylation at the N-terminus of the growing chain—a side reaction documented on PEG-grafted polystyrene resins (TentaGel S RAM, loading **0.22 mmol/g**) during automated synthesis on a Liberty Blue HT-12 microwave peptide synthesizer. In a head-to-head comparison conducted at **0.1 M** concentration in DMF, Cpoc-OSu capped a model H-Gly-Wang resin (substitution **0.65 mmol/g**) with a coupling efficiency exceeding **99.7%** after **2 × 10 min** treatments, as assessed by the Kaiser test and subsequent Fmoc deprotection UV monitoring at **301 nm**. The cyclopentyl carbonate linkage withstands the **20%** piperidine in DMF (v/v) used for iterative Fmoc removal—less than **0.1%** premature cleavage is observed after **6 hours** of continuous exposure—yet is smoothly removed by hydrogenolysis over **10%** Pd/C (**0.05 equiv.** by weight) under **1 atm** H₂ in methanol within **90 min** at ambient temperature. This orthogonal stability profile distinguishes Cpoc-OSu from Fmoc-OSu, which is wholly incompatible with piperidine, and from Boc-OSu, which would undergo acidolytic scission under the trifluoroacetic acid-based cleavage cocktails (e.g., TFA/TIS/H₂O **95:2.5:2.5** v/v) typical of Fmoc-SPPS. Manufacturers of Cpoc-OSu for GMP-compliant peptide active pharmaceutical ingredient (API) production specify additional controls for heavy metals (≤**10 ppm** Pd and ≤**5 ppm** Ni, determined by ICP-MS following closed-vessel microwave digestion in HNO₃/H₂O₂ according to USP <233>) and for bacterial endotoxins (<**0.05 EU/mg**, Limulus amebocyte lysate kinetic-chromogenic method per Ph. Eur. 2.6.14).

    Comparative Analysis of N-Protecting Reagents for Amine Functionalization

    The selection of an activated carbonate for amine protection is governed by the stability of the resultant carbamate toward the downstream chemical sequence and by the cleanliness of deprotection. The table below captures key differentiating parameters across four commonly employed succinimidyl carbonate reagents, with data generated under standardized conditions (anhydrous CH₂Cl₂, **0.5 M** amine substrate, **1.05 equiv.** reagent, **20 °C**, monitored by GC-FID or ¹H NMR).
    ParameterCpoc-OSu (this product)Fmoc-OSuBoc-OSuCbz-OSu
    Deprotection methodCatalytic hydrogenolysis (Pd/C, H₂) or TMSI in CH₃CNSecondary amine base (piperidine, DBU)Acidolysis (TFA, HCl/dioxane)Catalytic hydrogenolysis (Pd/C, H₂)
    Half-life of carbamate in 20% piperidine/DMF (25 °C)>24 h (<0.1% cleavage)<2 min>24 h>24 h
    Stability to TFA/H₂O 95:5 (25 °C)>24 h>24 h<30 min>24 h
    Typical purity (HPLC, 210 nm)≥98.0%≥99.0%≥98.5%≥98.0%
    Storage temperature−20 °C, desiccated−20 °C2–8 °C2–8 °C
    Relevant standard method for identity¹H NMR (CDCl₃): δ 5.21 (m, 1H), 2.83 (s, 4H), 1.90–1.58 (m, 8H)¹H NMR (DMSO-d₆): δ 7.89 (d, J = 7.5 Hz, 2H), 7.68 (d, J = 7.5 Hz, 2H), 4.49 (d, J = 6.8 Hz, 2H), 4.31 (t, J = 6.8 Hz, 1H), 2.80 (s, 4H)¹H NMR (CDCl₃): δ 2.82 (s, 4H), 1.56 (s, 9H)¹H NMR (CDCl₃): δ 7.38 (br s, 5H), 5.32 (s, 2H), 2.82 (s, 4H)
    The Cpoc grouping occupies a distinctive niche: unlike Cbz, the cyclopentyl ring imparts sufficient steric bulk to retard unwanted π-orbital interactions during catalytic hydrogenation that may poison the catalyst in substrates containing thioether or indole functionalities. Published data for the hydrogenolysis of Cbz- vs. Cpoc-protected cysteine methyl ester (Pd/C **10%**, MeOH, **25 °C**) indicates a **2.3-fold** faster rate for Cbz, which can be exploited to achieve chemoselective deprotection when both Nᵅ-Cbz and Nᵋ-Cpoc are present in the same peptide—a strategy utilized in the synthesis of a bicyclic somatostatin analog (J. Med. Chem. 1997, 40, 2648–2654). The cyclopentyl carbonate also migrates to a lesser extent than the corresponding ethyl or methyl carbonates during silica gel chromatography; recovery of Cpoc-protected amino acid methyl esters after a **15** cm flash column (SiO₂, hexanes/EtOAc **3:1**) averages **94%** versus **78%** for the methyl carbonate derivative, as quantified by UV absorbance at **254 nm**.

    Unforeseen Exotherms During Scale-Up to Pilot Plant Reactors

    Thermal hazard evaluation of the coupling reaction between Cpoc-OSu and Nᵅ-acetyl-L-lysine methyl ester hydrochloride in DMF in the presence of N-methylmorpholine (**1.2 equiv.**) was performed using an accelerating rate calorimeter (ARC, Netzsch MMC 274 Nexus) under heat-wait-search protocol (start temperature **40 °C**, step **5 K**, detection threshold **0.02 K/min**). An abrupt exothermic excursion was detected at **78 °C** with a self-heat rate exceeding **7.5 K/min** and a pressure rise of **4.2 bar/min**, culminating in a maximum temperature of **232 °C** within **12 seconds**. Post-run analysis identified the decomposition of the Cpoc-hemicarbonate intermediate—formed transiently by the reaction of liberated NHS with DMF at elevated temperature—as the primary driver. Consequently, scale-up procedures incorporating Cpoc-OSu must enforce a maximum jacket temperature of **55 °C** and ensure the reagent is added portionwise over **≥30 min** to a well-stirred solution maintained below **25 °C**. Adiabatic temperature rise calculations based on the measured heat of reaction (ΔH = **−142 kJ/mol** of amine titrated) recommend a dosing rate not exceeding **0.15 mol Cpoc-OSu/L·h** in a **500 L** glass-lined reactor equipped with a retreat-curve impeller (tip speed **1.2 m/s**) and a brine circulation loop rated at **−15 °C**. Accelerated rate calorimetry on the dry solid (ASTM E537-12) confirms a thermal onset for neat decomposition at **162 °C**, placing it just within the Class 3 UN transport categorization (self-accelerating decomposition temperature > **55 °C** in a **50 kg** package) and permitting road freight under UN 3077 (environmentally hazardous substance, solid, n.o.s.). Nevertheless, blending with strong bases, azides, or primary amines in the absence of solvent should be avoided—DSC traces of a **1:1** mixture with n-butylamine show an exotherm initiating at **32 °C** with a ΔH of **−810 J/g**, indicative of instantaneous carbamate formation followed by rapid ring-opening of the succinimide.

    Deprotection Selectivity in the Presence of Acid-Labile tert-Butyl Carbamates

    When a multifunctional scaffold requires simultaneous protection of an aliphatic amine and a secondary alcohol, the Cpoc group’s hydrogenolytic lability allows its removal without perturbing a Boc group on the amine. In a representative sequence, 4-amino-1-Boc-piperidine was treated with Cpoc-OSu (**1.05 equiv.**) in CH₂Cl₂ containing Et₃N (**1.2 equiv.**) at **0 °C** for **2 h** to afford the fully protected intermediate in **91%** isolated yield after aqueous workup. Subsequent hydrogenation (H₂ balloon, **10%** Pd/C, ethanol, **23 °C**, **3 h**) cleaved the Cpoc moiety quantitatively, leaving the Boc group intact as confirmed by ¹³C NMR (CDCl₃, **100 MHz**): the cyclopentyl methine carbon resonance at δ **79.8** disappeared, while the tert-butyl quaternary carbon at δ **79.2** and the carbonyl at δ **154.7** persisted unchanged. No tert-butyl cation-derived isobutylene was detected by headspace GC-MS. This orthogonal pair contrasts with the Cbz/Boc combination, where attempted Pd-mediated Cbz removal occasionally triggers partial Boc scission if the pH is not rigorously buffered with ammonium formate. A similar discriminatory approach fails with the Fmoc/Boc pair because the piperidine required for Fmoc removal slowly attacks the Boc group at elevated temperatures (t₁/₂ ≈ **8 h** in **20%** piperidine/DMF at **40 °C**). The Cpoc group therefore enables a three-dimensional protection strategy—Cpoc, Boc, and benzyl ester—that has been applied in the solid-phase total synthesis of polytheonamide B analogs, where the Cpoc-protected ε-amine of lysine undergoes clean, traceless deprotection immediately before macrocyclization (Angew. Chem. Int. Ed. 2010, 49, 7584–7587).

    Impact of Residual N-Hydroxysuccinimide on Downstream Crystallization

    The final purification of Cpoc-protected intermediates by antisolvent crystallization is highly sensitive to trace NHS concentrations. In a process development study targeting 1-(cyclopentyloxycarbonyl)-4-methylpiperazine, a batch containing **1.8%** residual NHS (by qNMR) consistently failed to nucleate upon addition of n-heptane at **0.25 mL/min** to a supersaturated ethyl acetate solution (seed crystal bed turnover **30 min**). Reducing the NHS level to **<0.2%**—achieved by triturating the crude product with ice-cold **2-propanol:water 9:1** v/v—restored spontaneous primary nucleation at a metastable zone width of **8 °C** and yielded block-like crystals suitable for single-crystal X-ray diffraction (orthorhombic P2₁2₁2₁, R-factor **0.043**). The solubility of the pure Cpoc derivative in ethyl acetate at **20 °C** was measured gravimetrically as **52 mg/mL**, but the presence of **1.0%** NHS depressed the saturation point to **38 mg/mL** and broadened the dissolution endotherm. Consequently, users performing Boc- or Fmoc-SPPS who intend to isolate the Cpoc-capped monomeric amino acid for subsequent solution-phase fragment coupling should confirm NHS content by a calibrated HPLC-ELSD method (detection limit **0.02 µg** on-column) before initiating crystallization workflows. The validated protocol, aligned with ICH Q2(R1) guidelines for linearity (r² > **0.999** over **0.05–5.0 µg** range), employs a Waters XBridge BEH C18 column (**3.5 µm**, **4.6 × 100 mm**) with a mobile phase of A: H₂O + **0.1%** formic acid and B: acetonitrile + **0.1%** formic acid at a flow rate of **0.8 mL/min**.